BioNxt Solutions Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was CAD 0.041589 million compared to CAD 0.116931 million a year ago. Net loss was CAD 1.91 million compared to CAD 2.6 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.04 a year ago.
For the nine months, sales was CAD 0.261246 million compared to CAD 0.128314 million a year ago. Net loss was CAD 5.02 million compared to CAD 12.13 million a year ago. Basic loss per share from continuing operations was CAD 0.06 compared to CAD 0.18 a year ago.